ENTEROSOBTION IN PAEDIATRIC PRACTICE: SELECTION OF OPTIMAL SORBENT, 2010
N.V. Nagornaya, M.P. Limarenko, M. Gorky National Medical University of Donetsk
In such a manner, Enterosgel® improves the efficiency of treatment of allergic diseases, due to the following mechanisms: 1) normalizes the function of the digestive tract and immune system; 2) restores the normal composition of intestinal microflora; 3) reduces antigenic load on the digestive system and immune barrier of the intestine; 4) reduces the level of sensitization; 5) binds food and non-food allergens in the digestive tract; 6) reduces the severity and duration of exacerbation of skin and respiratory allergies, increases the duration of remission and reduces the number of relapses.
CLINICAL EFFICACY OF ENTEROSORPTION IN TREATMENT OF MICROBIAL-INFLAMMATORY AND IMMUNOCOMPLEX KIDNEY DISEASES IN CHILDREN
I.V. Bagdasarova, Institute of Nephrology AMS of Ukraine, O.I. Osadchaya, А.М. Boyarskaya, Institute of Hematology and Transfusiology AMS of Ukraine, B.S. Sheyman, N.А. Voloshina, L.I. Medved Institute of Ecohygiene and Toxicology, the Ministry of Health of Ukraine.
The use of enterosorption with Enterosgel medication in combination therapy of children with acute pyelonephritis reduces the toxic load on the neutrophilic granulocytes and contributes to the preservation of functional activity of the given cells at subcompensated level, reducing the risk of generalization of infection and the development of associated complications.
The use of Enterosgel medication in combination therapy of children with acute glomerulonephritis promotes preservation of the functional activity of monocytes and optimization of their participation in the mechanisms of antigen presentation to immune cells, which reduces the risk of autoimmune complications.
APPLICATION OF ENTEROSORBENTS IN THE TREATMENT OF INTESTINAL INFECTIONS IN CHILDREN WITH CONCOMITANT ATOPIC DERMATITIS, 2015
Usenko D. V., Y. A. Gorelov, A. V. Rudyk
Acute enteric infections (AEI) are among the widely prevalent infectious diseases worldwide. The highest incidence of intestinal infections occur in pediatric populations . The main reason is biodiversity pathogens AEI: bacteria, viruses and protozoa from different taxonomic groups. Bacterial AEI can cause the genera Salmonella, Shigella, pathogenic strains of E. coli, spp. Clostridium, spp. Campylobacter spp., spp. Staphylococcus spp. Klebsiella, etc. Viral AEI pathogens are group A rotaviruses and noroviruses, astroviruses, F adenoviruses, sapoviruses. Discusses the role of group C rotaviruses, bocaviruses, Aichi virus, parechovirus, coronaviruses, etc. in the development of acute gastroenteritis.
ROTAVIRUS INFECTION IN NEWBORNS CHILDREN: CLINICAL PERFORMANCE, TREATMENT AND PROPHYLAXY, 2004
TUNDA I. P.
Health Care Practice has proposed effective preventive measures based on the results of clinical and virological studies and determining RVI leading risk factors in infants.
In the practice of maternity and neonatology departments, specialized clinical virological and microbiological monitoring of RVI in newborns has been offered for early diagnosis and prevention of nosocomial RVI.
In complex care unit optimum schemes and methods of administration of recombinant interferon - Laferon in the dose of 50-100,000 IU / kg 2 times a day, in enemas, within 3-5 days has been offered; Enterosgel in the dose of 5 g / kg 3 times a day orally for 5 days. To correct microflora, multyprobiotic Symbiter was applied in RVI treatment in 0.5 dose twice a day, orally, for 10 days.
THE MANAGEMENT OF ACUTE GASTROENTERITIS IN CHILDREN, 2012
M. Plescik-Lech, R. Shamir, A. Guarino, H. Szajewska
Efforts to improve the taste and/or efficacy of oral rehydration solution (ORS) continue, and some interventions are promising. While standard (over 24 h) nasogastric rehydration is still being used, new evidence confirms that
rapid (over 4 h) rehydration is also effective. For intravenous rehydration, new evidence is available regarding rapid or ultrarapid and large-volume vs. standard-volume rehydration; as the new evidence is not consistent, until
more data are available, the administration of 20 mL/kg seems appropriate.
Convincing evidence has accumulated showing that ondansetron reduces the risk for vomiting; however, a clearance on safety in children is needed. New evidence has reconfirmed that in Europe, where zinc deficiency is rare, there is no benefit from the use of zinc. New data, although mainly from outside of Europe, have reconfirmed that either smectite or racecadotril is an effective adjunctive therapy to oral rehydration. There is a clear effect of using certain probiotics, such as Lactobacillus GG or S. boulardii.
APPLICATION OF ENTEROSGEL IN COMPLEX TREATMENT OF NEONATES WITH PERINATAL PATHOLOGY, 2007
Mizgina T.I., Gurobska L.І., Goryachevska Т.М., Krykotenko L.V.
The article discusses the best practice of Enterosgel application in infants with perinatal pathology. High efficiency of Enterosgel has been shown in complex therapy of patients with neonatal hyperbilirubinemia, intestinal dysbiosis and other pathologies. Enterosgel has practically no side effects and is easy to use, being tolerated by the infants; it can also be used for fast and effective non-invasive detoxification.
ENTEROSORBENT ENTEROSGEL IN CLINICAL PRACTICE, 2016
ln order to assess the characteristics of the medical device ENTEROSGEL, establish the method of its use and the safety for users, this report was drawn up in the form of a critical evaluation of the relevant
published clinical studies conducted with ENTEROSGEL and with other at least partially comparable
medical devices already placed on the European market.
EFFICIENCY OF ENTEROSGEL IN CORRECTION OF SYSTEMIC ENDOTOXEMIA IN CHILDREN WITH ATOPIC DERMATITIS, 2016
T.G. Malanicheva, B.A. Shamov
Endotoxin aggression is developed with the expressed release of endotoxin (ET) in the bloodstream on the background of insufficient activity of excretory systems and is qualified as a universal mechanism involved in the pathogenesis of many infectious and non-infectious diseases . Systemic endotoxemia can develop as a result of both inactive intestinal microbiota, constant permeability disorders of the intestinal mucous membranes, and pancreatic insufficiency, biliary duct insufficiency, depression of liver barrier function or reduced portal blood flow, etc . ET presence affects immunocompetent blood cells and is one of the considerable stimulation factors of the immune system. Under physiological conditions, anti-endotoxin antibodies are released in response to ET presence . In pathological endotoxemia a decline of adaptive capacity and body resistance takes place [4, 5]. It is also known that endotoxemia causes cellular hypoxia, metabolic disorders, activation of sympathetic nervous system, complement system, resulting in lysis of leukocytes and platelet aggregation with the release of biologically active substances - kinins, histamine, serotonin, causing "mediator chaos."
All of the above has allowed us to make an assumption about the importance of systemic endotoxemia and endotoxin aggression in atopic dermatitis (AD) in children.
Objective: to define level of systemic endotoxemia in children with AD and evaluate drug Enterosgel (polymethylsiloxane polyhydrate) in complex therapy of the pathology.
EUROPEAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION/EUROPEAN SOCIETY FOR PEDIATRIC INFECTIOUS DISEASES EVIDENCE-BASED GUIDELINES FOR THE MANAGEMENT OF ACUTE GASTROENTERITIS IN CHILDREN IN EUROPE: UPDATE 2014
Alfredo Guarino, Shai Ashkenazi, Dominique Gendrel, Andrea Lo Vecchio, Raanan Shamir, Hania Szajewska
Gastroenteritis severity is linked to etiology, and rotavirus is themost severe infectious agent and is frequently associated with dehydration. Dehydration reflects severity and should be monitored by established score systems. Investigations are generally not needed. Oral rehydration with hypoosmolar solution is the major treatment and should start as soon as possible. Breast-feeding should not be interrupted. Regular feeding should continue with no dietary changes including milk. Data suggest that in the hospital setting, in non–breast-fed infants and young children, lactose-free feeds can be considered in the management of gastroenteritis. Active therapy may reduce the duration and severity of diarrhea. Effective interventions include administration of specific probiotics such as Lactobacillus GG or Saccharomyces boulardii, diosmectite or racecadotril. Anti-infectious drugs should be given in exceptional cases. Ondansetron is effective against vomiting, but its routine use requires safety clearance given the warning about severe cardiac effects. Hospitalization should generally be reserved for children requiring enteral/parenteral rehydration; most cases may be managed in an outpatients setting. Enteral rehydration is superior to intravenous rehydration. Ultrarapid schemes of intravenous rehydration are not superior to standard schemes and may be associated with higher readmission rates.
ABOUT EXPERIMENTAL PRECLINICAL SAFETY STUDYING OF THE MEDICINAL FORM OF A PREPARATION «ENTEROSGEL®,PASTE FOR INTAKE (SWEET)» GIVEN «TNK SILMA LTD.» (MOSCOW), 2010
THE STUDY DRUG SAFETY OF "ENTEROSGEL®, PASTA FOR INTAKE (SWEET)" ALLOWS TO RECOMMEND ITS SUBMISSION TO THE TO THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION AS LOW-TOXICITY DRUG AS THE PROCEDURE FOR EXPANDING INDICATIONS AND CHANGES IN INSTRUCTION FOR USE.
COLLECTION OF RESEARCH PAPERS. ENTEROSGEL RESEARCHES, 2015
Dzyublik I, Shunko Em, Barbova A. Clinical efficacy of Enterosgel in treatment of rotovirus infections in newborns
Gorodetsky, Tebechevsky F Clinical efficacy of Enterosgel in treatment of patients with hepatitis A
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of diarrhoea-dominant irritable bowel syndrome.
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of Helicobacter Pylori – associated chronic gastroduodentis
Astahov V., Gusev V. The Clinical Efficacy and safety of Enterosgel in complex prevention of fetoplacental dysfunction in pregnant women with earlier syphilis
Usenko D., Gorelov A. The Clinical Efficacy of Enterosgel, in treatment of intestinal infections in chidren with atopic dermatitis.
Radchenko V., Seliverstov P. The Clinical Efficacy and safety of Enterosgel in treatment of predialysis Cronic Renal Falure (CRF) patients.
Nakhashova V. The Clinical Efficacy of Enterosgel in treatment of patients with Chronic Pancreatitis
Karlyichuk A., Kulachek F. The Clinical Efficacy of Enterosgel in complex treatment and prophylaxis of post-operative intraperitoneal in complication of acute cholecystitis
Moroz L., Paliy M. Use of enterosorbent Enterosgel in complex therapy of acute viral hepatitis B with concomitant intestinal dysbiosis
Sokolov E., Majev I. Clinical efficacy of Enterosgel in patients with digestive system-relative pathology.
Paliy I., Tchernobroviy V. Clinical efficacy of Enterosgel in complex treatment of intestinal dysbiosis
Yurchenko A., Nikolaev V. Clinical efficacy of Enterosgel in treatment of intoxication and diarrhoea in patients with AIDS during antiretroviral therapy.
COLLECTION OF RESEARCH PAPERS. GASTROENTEROLOGY: NEW APPROACHES, 2014
Paliy I.G., Reznichenko I.G. A Modern View on the Issue of Enterosorption: Choosing the O ptimal Drug
Tkach S.M. Effectiveness of Enterosorbent Enterosgel in Combined Anti-Helicobacter Therapy for Patients with Peptic Ulcer Disease
Osadchaya O.I., Boyarskaya A.M. Clinical Effectiveness of Enterosorption in Reduction of Endogenous Intoxication Syndrome in Patients with Nonspecific Ulcerative Colitis
Osadchaya O.I., Shmatova E.A., Boyarskaya A.M. Role of Detoxification Therapy in Maintaining Toxin-binding Capacity of Peripheral Blood Albumin in Patients with Alcoholic Liver Disease
Zaytseva N.V., Aminova A.I., Akatova A.A., Minchenko Ye. Yu. Peculiarities of Eradication Therapy for Chronic H. pylori-associated Gastroduodenitis in Children Living in Ecologically Unfavorable Conditions
Fedorova O.V., Fedulova E.N., Tutina O.A., Korkotashvili L.V. Endogenous Intoxication in Inflammatory Bowel Disease in Children: Substantiation of Detoxification Therapy Using Enterosorption Method
Boyarskaya A.M., Osadchaya O.I., Zhernov A.A., Kovalenko O.N.Use of Enterosorbent Enterosgel in Combination Treatment of Intestinal Dysbiosis in Children with Burn Disease
Enterosgel® in Gastroenterology: Posology and Method of Administration
Dosage and Administration of Enterosgel® for the Treatment of Acute Diarrhea
COLLECTION OF RESEARCH PAPERS. ALLERGOLOGY, IMMUNOLOGY, DERMATOLOGY: NEW APPROACHES, 2013
J. Bystron: “...the basis of allergy management consists first and foremost of the identification of the causal allergen and the effort aimed at its elimination...”
Nagornaya N.V., Dubovaya A.V. The Detoxifying Potential and Clinical Effectiveness of the Enterosorbent Enterosgel in the Combination Therapy of Various Diseases in Children and Adults
Shamov B.A., Malanicheva T.G. Correction of Systemic Endotoxemia in Children with Atopic Dermatitis
Melnykov O.F., Zabrodska L.V., Tymchenko M.D., Sydorenko T.V., Naumova O.A. A Clinical and Immuno-Allergological Study of the Efficacy of Enterosgel in Food Allergy
Malanicheva T.G., Khaertdinova L.A. Enterosorption in the Treatment of Pediatric Atopic Dermatitis Complicated by Fungal Infection
Baranov A.A, Geppe N.A, Karpushkina A.V. The Efficacy of Enterosgel in the Treatment of Children with Bronchial Asthma and Atopic Dermatitis
J. Bystron. Application of Enterosorption Method with Organosilicon Enterosorbent Enterosgel in the Integrated Treatment of Allergic Diseases
Zaytseva N.V, Aminova A.I., Ustinova O.Yu., Akatova A.A., Luzhetskiy K.P. Asthma Prevention in Children with Recurrent Wheezing Bronchitis Who Have Elevated Levels of Heavy Metals and Aldehydes in the Body
Basieva O.Z., Basiev Z.G. Enterosgel in the Combination Treatment of Atopic Bronchial Asthma
Chorna O.O, Binda T.P. On the Issue of the Treatment of Children with Allergic Diseases
Enterosgel® in Allergology and Dermatology: Posology and Method of Administration
ENTEROSORBENTS THERAPY IN CHILDREN WITH ASTHMA LIVING IN POOR SANITARY CONDITIONS, 2013
Zaytseva N. , Usitnova O.
SUMMARY: According to recent epidemiological and toxicological data, children living in poor sanitary conditions develop abnormal physical characteristics, such as morphological abnormalities and chronic diseases of the Central Nervous System and the respiratory, cardiovascular, musculoskeletal, endocrine and digestive Systems. Among the substances of industrial origin, an important role is played by metals that accumulate in the tissues and organs. The toxic effects are due to the type of metal, its concentration, the concurrence of other pathological factors and the general health conditions (immune reactivity, hypersensitivity, etc.). The study was conducted on 236 children suffering from mild asthma (experimental Group) living in areas close to metallurgical plants. The composition of the air – concerning the percentage of manganese, chrome, lead and nickel – was found to have values at the upper limits of standard. The control Group, homogeneous for age, gender and residential area, consisted of 41 children. In order to reduce the blood concentrations of the considered toxic metals, 4 enterosorbents were tested and prescribed for 2 consecutive weeks of therapy: Enterosgel ®, Polysorb™, Polyphepan, and activated charcoal. – Enterosgel ® - blood tests. Decrease from baseline: Mn = 12%; Ni = 64 %; Pb = 20 %; Cr = 56 %. – Polysorb™ - blood tests. Decrease from baseline: Mn = 24%; Ni = 65%; Pb = 20 %; Cr = 66%. – Polyphepan - blood tests. Decrease from baseline: Mn = 0 %; Ni = 51 %; Pb = 12%; Cr = 61 %. – Activated charcoal - blood tests. Decrease from baseline: Mn = 0 %; Ni = 69 %; Pb = 10 %; Cr = 44%. Data reveal that the use of Enterosgel ® and Polysorb™ for 2 consecutive weeks allows to obtain a significant reduction – compared to the controls – of the amount of Cr and Ni (56-66%) and Mn and Pb (12-24%) in the blood of asthmatic children living in poor sanitary conditions.
The problem of elimination of toxic substances from the body is one of the most pressing in pediatrics. Hemosorption, hemodialysis and plasmapheresis has been successfully used in pediatric practice for a long time; however, the risk of their use may exceed expediency in some cases (for example, in case of moderate toxicity). Pediatricians have been always interested in non-invasive detoxification methods, in this context we have piloted Enterosgel, a new enterosorbent, in addition to infusion therapy, plasmapheresis, and in some cases as the unique detoxification therapy.
THE DETOXIFYING POTENTIAL AND CLINICAL EFFECTIVENESS OF THE ENTEROSORBENT ENTEROSGEL IN THE COMBINATION THERAPY OF VARIOUS DISEASES IN CHILDREN AND ADULTS, 2010
Nagornaya N.V., Dubovaya А.V.
The article describes different types of intoxication, presents a method of intracorporeal detoxification, and includes a classification of gastrointestinal adsorbents (enterosorbents). It summarizes the experience that has been gained with the intestinal adsorbent Enterosgel in the combination therapy of children and adults suffering from allergic diseases, gastrointestinal disorders, burn disease, chronic pyelonephritis, and recurrent non-specific vaginitis.
The comparative analysis of observation of two patient group (I group included the children received no Enterosgel (control) and II group included the children whose therapy involved this drug) showed that the improvement of the main clinical implications of disease (DRS) was diagnosed in the children received Enterosgel as a part of the complex therapy: in 75% of patients, the rash elements decreased in Day 3-4 after drug administration and Quicke's edema disappeared in Day 2-3 of treatment. The positive effect of the Enterosgel therapy on the dyspeptic syndrome was observed: stool was normalizaed and nausea was terminated. In 49% of patients, disappearance of the pain abdominal syndrome was noted. It should be said that, in children under 2 years, the improvement in the decrement of the main disease manifestations was less appreciable and more delayed. This is explained by the morphofunctional dismaturity of the gastrointestinal tract in children of this age (enzymatic and topical immunologic deficiency, late onset of the formation of intestinal microbiology). At the same time, in the control group children received no Enterosgel, the improvement of clinical signs of DRS was less considerable and diagnosed only in 22% of patients. Disappearance of the DRS syndromes, pain abdominal and dyspeptic syndromes was delayed up to 7-8 Day of the complex therapy.
Thus, based on the study performed, one can conclude that application of Enterosgel in the complex therapy of childhood allergic diseases is pathogenetically proved and reasonable.
It has been established that the incidence of renal diseases in children in the regions of cement industry is very high, especially regarding dysmetabolic nephropathy, unlike the control region, which shows the significant role of environmental factors in the development of renal damage. The conducted studies of Kudin M.V. (2012)  have shown that in children and adults living in the area and having no renal diseases cadmium - toxic element, hazard class 1 - accumulates in kidney tissue, which justifies the use of enterosorbent Enterosgel in persons living in the region as a prophylactic purpose.
Enterosgel not only prevents accumulation of toxic substances into the body by their intestinal adsorption, but also contributes to the removal of heavy metals from the urinary system. Inclusion of Enterosgel in the therapy of children with renal diseases living in the region of cement industry leads to the increased urinary excretion of cadmium, chromium, antimony, and arsenic and improvement of urinary symptoms and, above all, reduction of proteinuria, reflecting improved reabsorption function of the epithelium of proximal tubules.
No undesirable effects have been registered in children receiving Enterosgel.
ADSORPTION ACTIVITY OF ENTEROSGEL TOWARD ROTAVIRUS, 1997
Jilin V.N., Dzyublik I.V., Barbova A.I.
Every year the range of problems associated with use of sorption technologies in various fields of medicine is expanding. Growing use of sorption processes, in turn, leads to improvement of the properties of older types of sorbents and creation of new sorbents with improved properties and enhanced sorption selectivity toward certain substances. Comparative medico-biological studies of various polymeric materials has shown prospectivity of medical use of organopolysiloxane adsorbents, particularly of polymethylsiloxane (PMS) and its hydrogel, Enterosgel, which consists of a spatially cross-linked porous matrix with a rigid globular structure formed by siloxane chain containing methyl and partially uncondensed hydroxyl groups in silicon atoms. The presence of hydrocarbon radicals provides high affinity of Enterosgel to organic substances (organophilic properties), that is to the toxic metabolites of various nature. In contrast to the known carbon sorbents and highly dispersity silicas, Enterosgel is characterized by apparent selectivity.